EDMONTON, AB - Aurora Cannabis Inc. (NASDAQ: NASDAQ:ACB) (TSX: ACB), a leading global medical cannabis company based in Canada, has announced a research grant to the University of British Columbia (UBC), facilitated by a Genome British Columbia (Genome BC) funding initiative. The research project, titled "Genomics-enabled Aroma Breeding in Cannabis," is spearheaded by Dr. Jose Celedon from Aurora and Professor Joerg Bohlmann from UBC. The study aims to validate genetic and chemical markers for fruity aroma traits in cannabis, which are significant to consumer preferences and impact user experience.
The collaboration between Aurora and UBC is expected to advance Aurora's breeding program by incorporating greater precision and efficiency, focusing on consumer-desired traits. This effort is part of Aurora's broader strategy to enhance product quality and consumer satisfaction in the cannabis market.
Aurora Cannabis has recently patented a series of genetic and chemical markers for fruity aroma, discovered through its CanD diversity panel. The partnership with UBC will enable the company to validate these markers using state-of-the-art techniques, which would typically require substantial investment. The research's findings are anticipated to facilitate the development and introduction of new cannabis strains with distinctive and improved aromatic qualities.
Contributions from Aurora to this project include sensory analysis and bioinformatic analysis using proprietary software. UBC, with the support of Genome BC funding, will undertake tasks such as sequencing transcriptomes, analyzing volatile chemistry, and characterizing the genes responsible for fruity aromas in cannabis.
The success of this research could revolutionize the approach to breeding for specific aromas in cannabis and potentially strengthen Aurora's intellectual property related to aroma.
Aurora Cannabis remains committed to pushing the boundaries of cannabis research and development. The company serves both medical and consumer markets across Canada, Europe, Australia, and South America, with a portfolio of brands recognized for their quality and innovation.
This article is based on a press release statement. Aurora's common shares are traded on the NASDAQ and TSX under the symbol "ACB".
In other recent news, Aurora Cannabis has reported significant developments in both financial performance and operational advancements. The cannabis company has seen a 12% year-over-year increase in net revenue during the first fiscal quarter of 2025, reaching $83.4 million, driven largely by a 24% rise in international medical cannabis revenue. Additionally, Aurora achieved a record 69% adjusted gross margin in its medical cannabis sector and reported its first-ever positive free cash flow, maintaining a strong balance sheet with $182 million in cash and no debt.
The company's CEO, Miguel Martin, has been appointed to the additional role of Executive Chairman, a decision made unanimously by the company's board, aiming to foster unified leadership and streamline decision-making. In another significant development, Aurora secured a US Patent for "Methods of Determining Sensitivity to Photoperiod in Cannabis," which could revolutionize cannabis cultivation, particularly in high-latitude areas.
Aurora also launched the Luo CBD lozenge in Canada, in partnership with Vectura Fertin Pharma, marking Vectura Fertin Pharma's first entry into the Canadian medical cannabis market. Despite a decrease in consumer cannabis net revenue, Aurora's focus on medical cannabis and strategic international expansion positions it well for future growth. The company anticipates robust net revenue and adjusted gross margins in the cannabis business in the upcoming quarters, with expectations of continued positive adjusted EBITDA. These are recent developments that investors should monitor closely.
InvestingPro Insights
Aurora Cannabis Inc.'s recent research grant to the University of British Columbia aligns with the company's focus on innovation and product development in the competitive cannabis market. This strategic move could potentially strengthen Aurora's market position and intellectual property portfolio.
According to InvestingPro data, Aurora Cannabis has shown some positive financial indicators. The company's revenue growth stands at 12.3% over the last twelve months as of Q1 2023, with a gross profit margin of 53.76%. This suggests that Aurora is maintaining a healthy profit margin on its sales, which could be further improved by the development of new, consumer-preferred cannabis strains resulting from this research collaboration.
However, investors should note that Aurora Cannabis is currently not profitable, with an operating income of -$18.31 million over the last twelve months. An InvestingPro Tip indicates that the company is quickly burning through cash, which underscores the importance of successful research and development initiatives to drive future growth and profitability.
Another InvestingPro Tip reveals that Aurora's stock price movements are quite volatile. This volatility could be influenced by factors such as market reactions to research outcomes and product developments, making the success of projects like the UBC collaboration potentially significant for the company's stock performance.
For those interested in a deeper analysis, InvestingPro offers 7 additional tips for Aurora Cannabis, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.